You have read all your free articles, to continue reading subscribe to read the rest of this content.
Athera Biotechnologies has announced that two composition of matter patents have been allowed for antibodies with binding to phosphorylcholine, PC. The PC target is part of modified phospholipids and has been characterized as an active driver of vascular inflammation. The therapeutic antibodies cAlready a subscriber Login You have read all…
Nanoform Finland and Herantis Pharma have signed a letter of intent to collaborate to seek to enhance nasal drug delivery to the brain of Herantis’ CDNF and xCDNF therapies (Parkinson’s disease) using Nanoform’s biological nanoparticle technology. The planned and non-exclusive collaborationAlready a subscriber Login You have read all your free…
AstraZeneca has entered an agreement with Grünenthal for the global rights to Zomig (zolmitriptan) outside Japan. Zomig is indicated for the acute treatment of migraines and cluster headaches, an area of medicine outside AstraZeneca’s strategic focus. Grünenthal will pay AstraZeneca $200 Already a subscriber Login You have read all your free…
The supplemental Biologics License Application (sBLA) for Ultomiris (ravulizumab-cwvz) in adults with generalised myasthenia gravis (gMG) has been accepted for Priority Review by the US Food and Drug Administration (FDA). The FDA set a Prescription Drug User Fee Act date during the second quartAlready a subscriber Login You have read all your…
